Welcome to our dedicated page for Adapthealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AdaptHealth Corp. filings document the company’s healthcare-at-home operations, financial reporting and public-company governance. Its Form 8-K disclosures include quarterly and annual earnings releases, Regulation FD updates, financial guidance, business highlights and material events related to operating partnerships, asset dispositions and executive leadership changes.
The filing record also covers capital structure and financing matters, including credit agreements entered into by AdaptHealth LLC and related guarantees, collateral and borrowing commitments. AdaptHealth’s proxy materials describe board and executive compensation matters, while its securities disclosures identify common stock trading under AHCO on the Nasdaq Stock Market.
AdaptHealth Corp.'s Chief Accounting Officer, Christine E. Archbold, reported an equity award in the form of restricted stock units. On January 30, 2026, she acquired 32,213 shares of common stock, represented by restricted stock units that will be settled in common stock upon vesting at a price of $0 per share. Following this grant, she beneficially owns 107,198 shares of AdaptHealth common stock, held directly.
AdaptHealth Corp.'s Chief Financial Officer, Jason A. Clemens, reported an equity award of company stock. On January 30, 2026, he acquired 126,899 shares of Common Stock at a price of $0 per share, bringing his directly held beneficial ownership to 673,481 shares.
The newly reported shares represent restricted stock units that will be settled in common stock when they vest, providing the CFO with additional long-term, stock-based compensation tied to the company’s performance and continued service.
AdaptHealth Corp. director Theodore B. Lundberg reported acquiring 13,740 shares of AdaptHealth common stock on January 9, 2026. The filing shows the shares were received at a price of $0 per share and are described as restricted stock units that will be settled in common stock upon vesting. Following this transaction, Lundberg is shown as beneficially owning 873,496 shares of AdaptHealth common stock with direct ownership.
AdaptHealth Corp. director Gregory Belinfanti reported an equity award in the form of restricted stock units. On January 9, 2026, he was granted 11,776 shares of AdaptHealth common stock at a reported price of $0 per share, reflecting a compensatory award rather than an open‑market purchase. These shares are structured as restricted stock units that will be settled in common stock when they vest. Following this grant, Belinfanti directly beneficially owned 85,270 shares of AdaptHealth common stock.
AdaptHealth Corp. director David S. Williams III reported an open-market sale of 5,000 shares of the company’s common stock on December 4, 2025 at a price of $9.43 per share. After this transaction, he beneficially owns 45,045 shares of AdaptHealth common stock, held directly.
AdaptHealth Corp. (AHCO) reported Q3 2025 results. Net revenue was $820.3 million versus $805.9 million a year ago. Operating income was $61.7 million, and net income attributable to AdaptHealth was $24.5 million, or diluted EPS of $0.16 (vs. $0.15). Segment revenue totaled $354.8 million in Sleep Health, $177.0 million in Respiratory Health, $150.1 million in Diabetes Health, and $138.4 million in Wellness at Home.
On the balance sheet, long‑term debt (less current) was $1.74 billion and cash was $80.4 million as of September 30, 2025. Year‑to‑date, operating cash flow was $418.6 million, with a $32.2 million pre‑tax gain from the sale of two businesses closed on May 1 and June 9, 2025. For the nine months, depreciation and amortization (including patient equipment) was $284.4 million. As of October 31, 2025, there were 135,424,334 common shares outstanding.
AdaptHealth Corp. furnished an update on its recent performance by issuing a press release with financial results for the quarter ended September 30, 2025. The company released these results on November 4, 2025 and attached the full press release as an exhibit to this report.
The disclosure is provided under the results of operations and financial condition section and is treated as “furnished” rather than “filed,” which limits certain legal liabilities. The press release is identified as Exhibit 99.1, with an additional exhibit covering the interactive data for the cover page.
David S. Williams III, a director of AdaptHealth Corp. (AHCO), sold 8,200 shares on 08/22/2025 at a weighted average price of $9.73 per share. The filing shows the reported sales occurred in multiple transactions at prices ranging from $9.60 to $9.85, and the reporting person continues to beneficially own 50,045 shares following the transactions. The Form 4 was filed by one reporting person and signed by an attorney-in-fact, with a previously filed power of attorney incorporated by reference.
AdaptHealth Corp. 10-Q (Q2 2025) Reports net revenue of $800.4M for Q2 2025 and $1.578B for the six months ended June 30, 2025, relative to $806.0M and $1.598B a year earlier.
Operating income improved to $79.3M in Q2 driven by a $32.225M gain on sale of businesses; however, higher income tax expense ($35.9M in Q2) contributed to a Q2 net income of $15.8M and six-month net income of $9.7M, down vs. prior periods.
- Adjusted EBITDA declined to $155.5M in Q2 and to $283.5M for six months.
- Cash declined to $68.63M from $109.75M at year-end.
- Long-term debt decreased to $1.793B from $1.965B (repayments of $175.0M noted).
- Disposed two Wellness at Home businesses for gross proceeds of $120.835M and recognized related goodwill reductions.
AdaptHealth Corp. 10-Q (Q2 2025) Reports net revenue of $800.4M for Q2 2025 and $1.578B for the six months ended June 30, 2025, relative to $806.0M and $1.598B a year earlier.
Operating income improved to $79.3M in Q2 driven by a $32.225M gain on sale of businesses; however, higher income tax expense ($35.9M in Q2) contributed to a Q2 net income of $15.8M and six-month net income of $9.7M, down vs. prior periods.
- Adjusted EBITDA declined to $155.5M in Q2 and to $283.5M for six months.
- Cash declined to $68.63M from $109.75M at year-end.
- Long-term debt decreased to $1.793B from $1.965B (repayments of $175.0M noted).
- Disposed two Wellness at Home businesses for gross proceeds of $120.835M and recognized related goodwill reductions.